drugset / Trial / NCT00888810
Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer
Phase 2
Terminated
39 enrolled
Centre Francois Baclesse
Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète · collabGlaxoSmithKline · collab
NaSingle-groupOpen-labelTreatment
Summary
The objective of the trial was to evaluate the efficacy of the association of topotecan and lapatinib in patients who failed first line platinum-based chemotherapy within 12 months.
Timeline
- Start
- 2008-03
- Primary completion
- —
- Completion
- —
Outcome
Outcome not reported
Stopped: “lack of efficacy (intermediate analysis)”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lapatinib | Small molecule | 1250 mg | Oral |
| Subject | Topotecan | Small molecule | 3.2 mg/m2 | Intravenous |